Kawasaki Kenji

The story

Kenji is four. His fever has not broken in five days despite acetaminophen, his lips are cracked and bleeding, and his tongue looks like a strawberry.

Kenji's grandmother nicknamed him after the fevers that would not break no matter what she tried, a stubborn illness that struck when he was only three years old and refused every home remedy in her arsenal. What she was witnessing was Kawasaki disease, an acute vasculitis of small and medium arteries that strikes young children, most often under age five, and specifically targets the vessel walls of the coronary arteries. As inflammation weakens those delicate arterial walls, they can dilate into aneurysms that may later thrombose, threatening the very blood supply to the heart muscle itself. Kenji's name becomes an anchor for remembering that beneath the dramatic skin and mucous membrane findings of Kawasaki disease lies a silent, potentially devastating cardiac threat that only imaging and vigilant nursing surveillance can catch in time.

Kenji is brought to the emergency department by his frantic parents after five straight days of fever above 104°F that has not responded to repeated doses of acetaminophen or ibuprofen. His lips are cracked and strikingly red, his tongue has taken on a bumpy, strawberry-like texture, and his eyes show a nonpurulent, remarkably pink conjunctivitis without any discharge. His parents also point out that his hands and feet appear unusually red and swollen, and a faint rash covers his trunk. The pediatric team recognizes this constellation immediately as meeting the clinical criteria for Kawasaki disease, and given that Kenji is still within the first ten days of illness, they know timing is critical for starting treatment that can meaningfully reduce his risk of coronary damage.

As Kenji begins his intravenous immunoglobulin infusion, his nurse monitors him closely and notices new fine crackles at his lung bases along with a two-pound weight gain since admission, worrisome early signs of fluid overload from the large-volume infusion rather than his underlying illness. His cervical lymph nodes remain notably swollen and tender to palpation, and by day twelve of his illness his platelet count has surged to 780,000/mm3, an expected but striking laboratory finding of the recovering phase. His skin has begun peeling in sheets from his fingertips and toes, alarming his parents even though the nurse reassures them this desquamation is expected and not contagious. His echocardiogram is scheduled urgently to evaluate his coronary arteries for developing aneurysms.

Kenji's nurse administers the intravenous immunoglobulin exactly as ordered while carefully watching for signs of fluid overload throughout the infusion, promptly reporting the new crackles and weight gain to the provider for possible rate adjustment. She administers high-dose aspirin for its anti-inflammatory effect during the acute phase, understanding this is the classic pediatric exception where aspirin is appropriate rather than contraindicated, and anticipates transitioning to low-dose aspirin later for its antiplatelet effect. She educates Kenji's parents that his irritability may persist for weeks, that they should keep his environment calm and quiet, and that they must report any viral illness promptly because of his aspirin therapy's associated Reye syndrome risk. She stresses that every follow-up echocardiogram appointment is essential for tracking his coronary arteries.